What does MEN2 (Multiple Endocrine Neoplasia type 2) stand for?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 2, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

MEN2 Definition

MEN2 stands for Multiple Endocrine Neoplasia Type 2, a hereditary cancer syndrome caused by germline mutations in the RET proto-oncogene on chromosome 10q11.21 1.

Clinical Subtypes

MEN2 encompasses two main clinical variants with distinct features 1:

  • MEN2A (91% of cases): Characterized by medullary thyroid carcinoma (MTC) with >95% lifetime risk, pheochromocytoma in 50% of patients, and primary hyperparathyroidism in 20-30% of cases 1

  • MEN2B (9% of cases): The most aggressive form with 100% risk of MTC (often presenting in infancy), 50% risk of pheochromocytoma, mucosal neuromas, intestinal ganglioneuromatosis, marfanoid habitus, and notably no hyperparathyroidism 1

  • Familial Medullary Thyroid Carcinoma (FMTC): Now considered a variant of MEN2A with decreased penetrance of pheochromocytoma and hyperparathyroidism, accounting for 35% of MEN2A cases 1

Genetic Basis

The syndrome results from activating mutations in the RET proto-oncogene, a receptor tyrosine kinase 1, 2. The inheritance pattern is autosomal dominant with strong genotype-phenotype correlations 1. The de novo mutation rate is approximately 9% in MEN2A and as high as 50% in MEN2B 2, 3.

Prevalence

The estimated prevalence of MEN2 is 1:35,000 to 1:40,000 in the general population 1.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Multiple Endocrine Neoplasia Type 2 (MEN2) Diagnosis and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Multiple Endocrine Neoplasia Type 2 (MEN2)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.